Study guide

5.2 Inheritance of Blood Groups

Scientist in Blood Banking, BB ASCP

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility Routes and Application 1.3 CMP, Credential Citation, and BB vs SBB

2 Donors and Collection

2.1 Donor Qualification 2.2 Collection Methods and Adverse Reactions 2.3 Special Donations

3 Processing, Storage, and Component QC

3.1 Processing: FDA/AABB Requirements, Testing, and Labeling 3.2 Anticoagulants, Additives, and Storage Temperatures 3.3 Transportation, Stored-Product Properties, and Expiration 3.4 Blood Component Quality Control

4 Blood Components

4.1 Red Blood Cells, Whole Blood, Washed, Frozen, and Rejuvenated 4.2 Platelets, Plasma, and Cryoprecipitated AHF 4.3 Granulocytes, Leukoreduced, and Irradiated Components 4.4 Apheresis Products, Fractionation, and Hematopoietic Progenitors

5 Blood Group Genetics and Transfusion Role

5.1 Basic and Molecular Genetics 5.2 Inheritance of Blood Groups 5.3 Immunogenicity and Antigen Prevalence

6 ABO and Lewis Systems

6.1 ABO Biochemistry and Antigens 6.2 ABO Antibodies, Discrepancies, and Subgroups 6.3 Lewis System

7 Rh System

7.1 Rh Genetics and Antigens 7.2 Weak D, Partial D, and Rh Antibodies 7.3 Rh Phenotyping and Clinical Significance

8 Kell, Duffy, Kidd, and MNS

8.1 Kell System 8.2 Duffy System 8.3 Kidd System 8.4 MNS System

9 Additional Systems and Antigens

9.1 P1PK, Globoside, and Ii Systems 9.2 Lutheran and Other Blood Group Systems 9.3 High- and Low-Prevalence Antigens 9.4 HLA, Platelet-Specific, and Granulocyte-Specific Antigens

10 Immunology Foundations

10.1 Immune Response, B and T Cells, Macrophages 10.2 Immunoglobulins: Classes, Structure, and Properties 10.3 Antigen-Antibody Interactions and Testing 10.4 Complement Pathways and Biologic Properties

11 Physiology, Hemostasis, Cytopenias, and Transplantation

11.1 Physiology of Blood 11.2 Hemostasis and Coagulation 11.3 Immune and Nonimmune Cytopenias 11.4 Solid Organ and HPC Transplantation

12 Hemolytic Disease of the Fetus and Newborn

12.1 HDFN Pathophysiology 12.2 HDFN Detection 12.3 HDFN Treatment and Prevention

13 Routine Serologic Testing

13.1 Blood Grouping Tests 13.2 Antibody Detection 13.3 Compatibility Testing and Crossmatch 13.4 Direct Antiglobulin Testing

14 Antibody Identification

14.1 Antibody Identification and Rule-Out 14.2 Clinical Significance, Dosage, and Multiple Antibodies 14.3 Panel Problem-Solving and Common Traps

15 Reagents and Special Techniques

15.1 Antiglobulin Sera, Grouping Sera, and Reagent Red Cells 15.2 Enzymes, Enhancement Media, and Lectins 15.3 Adsorption, Elution, Titration, and Cell Separations 15.4 Molecular, Solid-Phase, Column, ELISA, and Related Methods

16 Serologic QA and Special Reagents

16.1 Blood Sample Quality Assurance 16.2 Reagent and Procedure Quality Assurance 16.3 Thiol Reagents, Neutralization, Chloroquine, EGA, and Immunofluorescence

17 Indications and Component Therapy

17.1 Indications for Transfusion 17.2 Red Cell and Whole Blood Therapy 17.3 Platelet, Plasma, and Cryoprecipitate Therapy 17.4 Special Component Therapy

18 Adverse Effects of Transfusion

18.1 Immunologic Transfusion Reactions 18.2 Nonimmunologic Transfusion Reactions 18.3 Transfusion-Transmitted Diseases

19 Apheresis, Administration, and Patient Blood Management

19.1 Apheresis and Extracorporeal Circulation 19.2 Blood Administration 19.3 Patient Blood Management

20 Laboratory Operations

20.1 Quality Assessment and Troubleshooting 20.2 Quality Control, Proficiency Testing, and Regulation 20.3 Laboratory Safety 20.4 Laboratory Mathematics and Instrumentation

5.2 Inheritance of Blood Groups

Key Takeaways Explain This Topic AI

Most RBC antigens show autosomal codominant expression: one producing allele is enough to type antigen-positive, and heterozygotes express both antithetical antigens.

ABO: A and B are codominant; O is an amorph. Bombay (hh) is FUT1 epistasis — no H, so no A or B on red cells even if the ABO genotype is A or B — and the serum contains anti-H.

RH haplotypes travel as a block. Wiener/Fisher-Race: R1 = DCe (most common European D+), r = dce (most common European D−), R2 = DcE, R0 = Dce (most common African haplotype), then r', r'', Rz, ry.

If an antigen’s frequency is 91%, the antigen-negative rate is 9%. Units to screen ≈ units needed / 0.09 (about 23 units to find two negatives). Multiply independent negative frequencies for multiple antigens.

Dosage: homozygotes react stronger (Rh, Kidd, Duffy, MNS). XK (Kx/McLeod) and XG are the X-linked systems. HDFN Punnett squares start with paternal zygosity, not a guess from the mother’s type.

Last updated: August 2026

5.2 Inheritance of Blood Groups

Quick Answer: Most red-cell antigens are autosomal and expressed whenever one inherited allele can make them — the alleles are codominant , so a heterozygote types antigen-positive. ABO : A and B are codominant , O is an amorph . Bombay (hh) is epistasis : no H, so no A or B on red cells even if the ABO genotype is A or B. RH haplotypes are written in Wiener or Fisher-Race: R1, r, R2, R0, r', r'', Rz, ry . Hardy–Weinberg turns an antigen frequency into the antigen-negative rate you use to calculate how many units to screen. Dosage means homozygotes react stronger. XK (Kx) and XG are the X-linked systems. Punnett squares for HDFN start with paternal zygosity .

Mendelian expression, said the way the exam says it

Red-cell antigens are not classic complete-dominance traits like brown eyes. Both parental alleles are usually transcribed, and both antigens appear on the cell. That is codominance . A K+k+ person expresses K and k. A Fy(a+b+) person expresses both Duffy antigens. The older outline phrase “autosomal dominant expression” still appears on the June 9, 2026 guideline and in stems; it means a single inherited producing allele is enough to type antigen-positive. It does not mean the antithetical antigen is suppressed. If a question asks why a child of a K+k+ parent and a K−k+ parent can be K−, the answer is Mendelian segregation of KEL 01 versus KEL 02, not “K is recessive.”

Almost every protein blood-group system is autosomal . The two X-linked exceptions you must name are XK (Kx antigen; McLeod phenotype when silenced) and XG (Xga). An XK-null male (McLeod) has no Kx, weakened Kell antigens, and acanthocytes; when the deletion also removes CYBB , chronic granulomatous disease travels with McLeod. A female can be mosaic. Do not put Kidd, Duffy, or KEL on the X chromosome.

ABO: codominance plus an amorph, then Bombay epistasis

At the ABO locus (chromosome 9), ABO A and ABO B encode glycosyltransferases that add GalNAc or galactose to H substance. They are codominant . ABO O is an amorph — no functional transferase — so group O is the homozygous silent genotype. A group A person is AA or AO ; serology cannot see that difference. A and B on the same person produce group AB.

Bombay (O_h) is not another O allele. It is epistasis at FUT1 (H). An hh person cannot make H on red cells. Without H, A and B transferases have nothing to decorate, so the red cells type as group O even when the ABO genotype is A, B, or AB . The serum contains anti-H (plus anti-A and anti-B), which is why Bombay blood is incompatible with every ordinary O unit — ordinary O cells are packed with H. Only Bombay units are compatible. Secretor ( FUT2 ) is a related but distinct locus: it puts H, A, and B in saliva. Do not call Bombay “group O with a strong anti-H” and stop; the genetic diagnosis is hh epistasis, not an O/O genotype.

A Punnett square for two AO parents is the classic 1 AA : 2 AO : 1 OO (phenotypes 3 A : 1 O). A group AB × group O pairing yields A and B children only — never AB or O — unless cis-AB or a typing error is in play.

RH haplotypes: two genes, one inheritance block

RHD and RHCE sit adjacent on chromosome 1 and almost always travel as a haplotype . In people of European ancestry, D− almost always means deleted RHD with RHCE still present (the dce or r haplotype). In people of African ancestry, D− is often an inactive RHD ( RHD psi, the 37-bp insertion pseudogene) or a hybrid, not a clean deletion. RHCE encodes C/c and E/e. There is no antithetical “d” antigen; d is a placeholder for the absence of D.

Wiener shorthand and Fisher-Race epitopes describe the same eight common haplotypes :

Wiener Fisher-Race Antigens on that haplotype Approx. frequency (European) Approx. frequency (African ancestry)

  • R1 DCe D, C, e 0.42 (most common D+ European) 0.17
  • r dce c, e (no D) 0.37 (most common D− European) 0.26
  • R2 DcE D, c, E 0.14 0.11
  • R0 Dce D, c, e 0.04 0.44 (most common African haplotype)
  • r' dCe C, e (no D) 0.01 uncommon
  • r'' dcE c, E (no D) 0.01 uncommon
  • Rz DCE D, C, E rare rare
  • ry dCE C, E (no D) very rare very rare

A European D+ C+ c+ E− e+ person is almost always R1r (DCe/dce), not R1R0, because r is so common. An African-ancestry D+ C− c+ E− e+ person is often R0R0 or R0r . That haplotype difference is why C is much less common in African-ancestry donors and why R0 red cells are the phenotype you hunt for some sickle-cell matching protocols. G (RH12) rides with C or D; a dce/dce person is G− and can make anti-G, which looks like anti-D+C on a panel.

Hardy–Weinberg and the two-unit search

Antigen frequency in a stated population is a phenotype frequency . If the antigen-positive phenotype frequency is given, the antigen-negative frequency is 1 minus that number . You do not need q-squared if the stem already gives the antigen frequency. The blood-bank arithmetic the exam wants:

Units you must screen ≈ (number of units needed) / (antigen-negative frequency).

Worked example the outline flags: antigen frequency 91% , so antigen-negative = 9% = 0.09 .

  • Need Calculation Units to screen (round up)
  • 1 antigen-negative unit 1 / 0.09 12 (11.1 → 12)
  • 2 antigen-negative units 2 / 0.09 23 (22.2 → 23)
  • 3 antigen-negative units 3 / 0.09 34

If you must satisfy two independent antigens, multiply the negative frequencies first. Example: E− (about 70% of European-ancestry units) and K− (about 91%): 0.70 × 0.91 = 0.637. Two E−K− units require about 2 / 0.637 ≈ 4 units screened — not 23. Using 91% as if it were the negative rate, or forgetting to multiply independent frequencies, is the usual miss. Always use the patient’s ancestry-appropriate table , not a single “U.S.” column. Inverse trap: K itself is only ~9% in European donors, so K− is 91% and two K− units need only about 2 / 0.91 ≈ 3 units — do not apply the 91%-positive example to K by accident.

Hardy–Weinberg p² + 2pq + q² = 1 is how you estimate homozygote versus heterozygote counts when a stem gives an allele (not antigen) frequency. If the K allele frequency is about 0.05, KK ≈ 0.0025, Kk ≈ 0.095, kk ≈ 0.90 — matching the familiar “9% K+, almost all heterozygotes.” That is why anti-K rarely shows dosage: almost every K+ panel cell is Kk.

Dosage

Dosage is stronger agglutination with homozygous cells than with heterozygous cells. Antibodies that classically show dosage: Rh (especially anti-c, anti-E, anti-C), Kidd, Duffy, MNS (M, N, S, s) . Anti-K usually does not , because KK cells are rare. A weak anti-Jka may miss a Jk(a+b+) cell and react only with Jk(a+b−). When you rule out, you need a homozygous (double-dose) cell. Dosage is a serologic consequence of inheritance, not a different antibody.

Punnett squares for HDFN risk

Hemolytic disease of the fetus and newborn risk is a paternal zygosity problem. Mother is antigen-negative and already alloimmunized (or D− and a candidate for RhIG counseling).

  • Mother Father Offspring antigen-positive
  • D− (no RHD ) RHD / RHD (e.g., R1R1 or R1R2) 100% D+
  • D− RHD /deleted (e.g., R1r) 50% D+
  • K− ( KEL 02/ KEL 02) K+k+ ( KEL 01/ KEL 02) 50% K+
  • K− K+k− ( KEL 01/ KEL 01) 100% K+

Paternal RHD zygosity is why you order a molecular copy-number assay on the father instead of guessing from the C/c E/e phenotype. Phenotype can suggest zygosity (a D+ C+ c+ E− e+ European is probably R1r, hence heterozygous), but R0R0 versus R0r in African ancestry is not obvious from C and E. Fetal genotyping from maternal plasma answers the same question without assuming paternal relationship. A “50% of children will be D+” stem is describing a heterozygous father, not a law of ABO.

Loading diagram... Two-unit antigen-negative search from a 91% antigen frequency